Methods of diagnosing and treating tuberculosis
This disclosure relates to methods of treating and diagnosing a tuberculosis infection as pulmonary active or latent based on biomarkers expressed on pools of CD4 + cells. In certain embodiments, the disclosure relates to methods of treatment of a subject diagnosed with tuberculosis comprising the steps of, measuring a pool of CD4 IFN-γ cells for cells that also express CD38, HLA-DR, and/or Ki-67 providing a measurement; associating an increased measurement of CD4 IFN-γ cells that also express CD38, HLA-DR, Ki-67, compared to a control, as an indication that the subject has active tuberculosis; and treating the subject with an aggressive tuberculosis treatment.
1. A method of diagnosing and treating a subject with tuberculosis comprising the steps of,
measuring a pool of CD4 IFN-γ cells for cells that also express CD38, HLA-DR, and Ki-67 providing a measurement;
associating an increased measurement of CD4 IFN-γ cells that also express CD38, HLA-DR, Ki-67, compared to a control, as an indication that the subject has active tuberculosis infection, providing a subject diagnosed with an active tuberculosis infection,
wherein the increased measurement of CD4 IFN-γ cells that also express CD38, HLA-DR, Ki-67, compared to a control is a quantification that,
greater than 18% of the CD4 IFN-γ cells also express CD38;
greater than 60% of the CD4 IFN-γ cells also express HLA-DR; and
greater than 5% of the CD4 IFN-γ cells also express Ki-67; and
administering to the subject diagnosed with an active tuberculosis infection an aggressive tuberculosis treatment.
2. The method of claim 1 , wherein the aggressive tuberculosis treatment comprises administering a combination of more than two antibacterial agents.
3. The method of claim 1 , wherein the aggressive tuberculosis treatment comprises administering a combination of isoniazid, rifampicin, pyrazinamide, and ethambutol.
4. The method of claim 1 , further comprising the steps of,
measuring a second pool of CD4 IFN-γ cells for the quantity of cells that also express CD38, HLA-DR, and Ki-67;
associating a deceased measurement of CD4 IFN-γ cells that also express CD38, HLA-DR, Ki-67, compared to the increased measurement, as an indication that the subject has a latent tuberculosis infection, providing a subject diagnosed with a latent tuberculosis infection; and
administering to the subject diagnosed with a latent tuberculosis infection a less aggressive tuberculosis treatment.
5. The method of claim 4 , wherein the less aggressive tuberculosis treatment is only one or not more than a combination of two antibacterial agents.
6. The method of claim 4 , wherein the less aggressive tuberculosis treatment is a combination of only isoniazid and rifampicin.
7. The method of claim 1 , wherein the measurement, quantification, or indication is recorded on a computer readable medium.
8. The method of claim 7 , wherein the measurement, quantification, or indication is communicated to a medical professional or the subject.